Long-Term Safety Assessment of Biologic and Targeted Synthetic DMARDs
Overview
This longitudinal study evaluates the long-term safety of biologic and targeted synthetic DMARDs in rheumatoid arthritis, noting that tocilizumab was associated with higher hospitalization rates compared to etanercept, while tofacitinib showed an increased risk of gastritis.
Background
Rheumatoid arthritis (RA) is a chronic autoimmune disease that can lead to significant functional disabilities. Biologic and targeted synthetic DMARDs are essential for managing RA, especially after standard therapies fail. Understanding the safety profiles of these treatments is crucial for clinicians.
Data Highlights
No specific numerical data or trial data provided in the source.
Key Findings
Tocilizumab is linked to a higher rate of hospitalization compared to etanercept.
Tofacitinib is associated with an elevated risk of gastritis.
Advanced statistical methods were employed to account for biases in observational data.
The study utilized a large electronic medical records database for safety comparisons.
Clinical Implications
The findings highlight the need for robust safety data to guide treatment strategies.
Conclusion
The study highlights the importance of advanced methodologies in evaluating long-term treatment outcomes.
A Geneva registry study points surgeons toward residual pain over functional limitation as the outcome that tracks patient satisfaction one year after hip or knee replacement.
